1
NSG 533 Advanced Pharmacology Exam 3 Practice Questions
Advanced / Hard / Mixed Difficulty Target Audience:
Graduate Nursing Students, NP Candidates 100% Pass
Guaranteed | Graded A+
Question 1
In determining the appropriate dose of T4 replacement for a patient to re-establish a euthyroid
state, the nurse practitioner should primarily consider which factor?
A. The patient's TSH value
B. The patient's T4 level
C. The patient's body weight
D. The patient's gender
Correct Answer: C
Explanation: Replacement is based on body weight and is usually calculated in kg. The
patient's weight is the primary determinant for initial dosing, rather than TSH or T4 values,
which are used for monitoring .
,2
Question 2
For a patient with treatment-resistant depression who is started on a monoamine oxidase
inhibitor (MAOI), which over-the-counter medication must be strictly avoided due to the risk of
hypertensive crisis?
A. Loratadine
B. Dextromethorphan
C. Omeprazole
D. Acetaminophen
Correct Answer: B
Explanation: Dextromethorphan inhibits serotonin reuptake and can cause serotonin
syndrome when combined with MAOIs. It also has sympathomimetic effects that may contribute
to hypertensive crisis. Loratadine, omeprazole, and acetaminophen are generally considered
safe with MAOIs .
Question 3
According to current AHA/ACC/HRS guidelines, which anticoagulant has the most favorable net
clinical benefit for a patient with atrial fibrillation and stable coronary artery disease?
,3
A. Warfarin with a target INR of 2.0-3.0
B. Rivaroxaban 20 mg once daily
C. Apixaban 5 mg twice daily
D. Dabigatran 150 mg twice daily
Correct Answer: C
Explanation: Apixaban has demonstrated the most favorable safety profile with lower
major bleeding risk compared to warfarin and other DOACs in AF trials. It is preferred in patients
with CAD due to reduced intracranial hemorrhage and gastrointestinal bleeding. Rivaroxaban
and dabigatran are effective but have higher bleeding rates in some analyses .
Question 4
Which biologic agent would be most appropriate for a patient with severe asthma, an
eosinophilic phenotype, and concurrent chronic rhinosinusitis with nasal polyps?
A. Omalizumab
B. Mepolizumab
C. Benralizumab
D. Dupilumab
, 4
Correct Answer: D
Explanation: Dupilumab (anti-IL-4/IL-13) is indicated for both moderate-to-severe asthma
with eosinophilic phenotype and chronic rhinosinusitis with nasal polyps, addressing both
conditions simultaneously. Omalizumab targets IgE; mepolizumab and benralizumab target IL-
5/IL-5R and are primarily for eosinophilic asthma but are not specifically indicated for nasal
polyps .
Question 5
A patient with Parkinson's disease is experiencing motor fluctuations despite optimized
levodopa therapy. Which adjunctive medication is most likely to reduce 'off' time without
worsening dyskinesias?
A. Ropinirole
B. Entacapone
C. Selegiline
D. Amantadine
Correct Answer: B
Explanation: Entacapone, a COMT inhibitor, extends the duration of levodopa's effect and
NSG 533 Advanced Pharmacology Exam 3 Practice Questions
Advanced / Hard / Mixed Difficulty Target Audience:
Graduate Nursing Students, NP Candidates 100% Pass
Guaranteed | Graded A+
Question 1
In determining the appropriate dose of T4 replacement for a patient to re-establish a euthyroid
state, the nurse practitioner should primarily consider which factor?
A. The patient's TSH value
B. The patient's T4 level
C. The patient's body weight
D. The patient's gender
Correct Answer: C
Explanation: Replacement is based on body weight and is usually calculated in kg. The
patient's weight is the primary determinant for initial dosing, rather than TSH or T4 values,
which are used for monitoring .
,2
Question 2
For a patient with treatment-resistant depression who is started on a monoamine oxidase
inhibitor (MAOI), which over-the-counter medication must be strictly avoided due to the risk of
hypertensive crisis?
A. Loratadine
B. Dextromethorphan
C. Omeprazole
D. Acetaminophen
Correct Answer: B
Explanation: Dextromethorphan inhibits serotonin reuptake and can cause serotonin
syndrome when combined with MAOIs. It also has sympathomimetic effects that may contribute
to hypertensive crisis. Loratadine, omeprazole, and acetaminophen are generally considered
safe with MAOIs .
Question 3
According to current AHA/ACC/HRS guidelines, which anticoagulant has the most favorable net
clinical benefit for a patient with atrial fibrillation and stable coronary artery disease?
,3
A. Warfarin with a target INR of 2.0-3.0
B. Rivaroxaban 20 mg once daily
C. Apixaban 5 mg twice daily
D. Dabigatran 150 mg twice daily
Correct Answer: C
Explanation: Apixaban has demonstrated the most favorable safety profile with lower
major bleeding risk compared to warfarin and other DOACs in AF trials. It is preferred in patients
with CAD due to reduced intracranial hemorrhage and gastrointestinal bleeding. Rivaroxaban
and dabigatran are effective but have higher bleeding rates in some analyses .
Question 4
Which biologic agent would be most appropriate for a patient with severe asthma, an
eosinophilic phenotype, and concurrent chronic rhinosinusitis with nasal polyps?
A. Omalizumab
B. Mepolizumab
C. Benralizumab
D. Dupilumab
, 4
Correct Answer: D
Explanation: Dupilumab (anti-IL-4/IL-13) is indicated for both moderate-to-severe asthma
with eosinophilic phenotype and chronic rhinosinusitis with nasal polyps, addressing both
conditions simultaneously. Omalizumab targets IgE; mepolizumab and benralizumab target IL-
5/IL-5R and are primarily for eosinophilic asthma but are not specifically indicated for nasal
polyps .
Question 5
A patient with Parkinson's disease is experiencing motor fluctuations despite optimized
levodopa therapy. Which adjunctive medication is most likely to reduce 'off' time without
worsening dyskinesias?
A. Ropinirole
B. Entacapone
C. Selegiline
D. Amantadine
Correct Answer: B
Explanation: Entacapone, a COMT inhibitor, extends the duration of levodopa's effect and
